更新于 3月19日

(Senior) Scientist, Protein Expression

1.5-2.2万·14薪
  • 上海浦东新区
  • 3-5年
  • 硕士
  • 全职
  • 招1人

职位描述

蛋白纯化工艺蛋白表达
The successful candidate will play a role in BeiGene’s biologics area focusing on stable cell pool/line development, cell line engineering, recombinant protein/antibody production and production platform development.

The candidate will join a team of internal & external biologics working across multiple projects.

Responsibilities:
- Design and conducting recombinant protein expression.
- Design and develop stable cell pool/line for recombinant protein production.
- Upstream process development for recombinant protein production platform and specific projects supported.
- Cell line engineering with CRISPR/overexpression/RNA interference technology.
- Demonstrated laboratory skills in recombinant protein/Ab expression, cell line development and cell line engineering.
- Good skills in mammalian expression system (CHO/HEK) are highly preferred.
- Other work assigned by line manager.
Qualiligications Required:
- MSc in molecular biology, biochemistry, cell biology, protein engineering or related discipline. Bachelor’s degree with minimum 2 years of work experiences.
- Expertise in cell cryopreservation, thaw, passaging, routine culture, cell cloning, and cell banking.
- Experience with mammalian cell transfection, genome editing, and characterization.
- Skill with WAVE system and bioreactor is a plus but not required.
- Skill with automated workstation is a plus but not required.
- Strong problem-solving skill and able to work independently.
- Candidate who demonstrates accountability, an outcome-focused mindset, a proactive approach, and a high degree of self-motivation.
- The ability to effectively communicate and collaborate with diverse teams.
- Good oral and written communication skills in Chinese; similar skill in English is a plus but not required.

工作地点

百济神州(上海)医药研发有限公司
以担保或任何理由索要财物,扣押证照,均涉嫌违法。一经发现,

职位发布者

张婧媛/人事经理

当前在线
立即沟通
百济神州北京
About BeiGene BeiGene is a publically traded(BGNE, NASDAQ), globally focused biopharmaceutical company dedicated to becoming a leader in the discovery and development of innovative, molecularly targeted and immuno-oncology drugs for the treatment of cancer. Our cancer biology platform addresses the importance of tumor-immune system interactions and the value of primary tumor biopsies in developing new cancer models. We have a global team of over 200 individuals, including over 150 scientists and clinicians, and a world-renowned scientific advisory board, with deep scientific talent, extensive pharmaceutical experience, and a commitment to improving the lives of cancer patients around the world. Our clinical pipeline is comprised of novel oral small molecules and monoclonal antibodies(mAb) for cancer, including an anti-PD-1 monoclonal antibody, a best-in-class BTK inhibitor, a RAF dimer inhibitor, a best-in-class PARP inhibitor, and a variety of combination clinical studies. In addition, our robust preclinical programs are expected to generate more small molecule and mAb drugs for clinical development in coming years. For more information, please visit our website at www.beigene.com.
公司主页